Wednesday, June 15, 2016

ECDC Rapid Risk Assessment On MCR-1

  


# 11,460


Yesterday we looked at a CDC HAN: Alerting Healthcare Facilities Of 1st MCR-1 Gene Detection In US Patient and today we have a Rapid Risk Assessment by the ECDC on the growing threat of colistin resistant bacterial infections.

Despite huge gaps in surveillance data, the ECDC does their usual thorough job of presenting what is known about the threat.  

Follow the link to download the full report.


Plasmid-mediated colistin resistance in Enterobacteriaceae

PDF FILE
15 Jun 2016

​The recently recognised global distribution of a self-transferable plasmid-borne colistin resistance gene (mcr-1) poses a substantial public health risk to the EU/EEA because it further limits treatment options in patients with infections caused by multidrug-resistant gram-negative bacteria. It can spread colistin resistance more easily between bacteria and humans than chromosomal mutation.

MDR gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae strains that acquire the mcr-1 gene, remain susceptible to only a few antimicrobial agents, which means that infections caused by these strains are very difficult to treat.


This is a topic we've covered extensively in the past, going back to November of last year when the first cases were announced.  A partial list of earlier blogs includes:



CDC Statement On 1st MCR-1 Colistin Resistant Infection in U.S. 

EID Journal: Possible Transmission Of MCR-1 Harboring E. coli Between Companion Animals & Humans

Eurosurveillance Editorial: Plasmid-Mediated Colistin Resistance (MCR-1 gene):The Story Unfolds

Referral: McKenna On The Latest MCR-1 Findings 

MCR-1: The Return Of The Plasmids

 

No comments: